Literature DB >> 2811064

Activation of immunocompetent cells in the peritoneum of patients treated with CAPD.

S J Davies1, J Suassuna, C S Ogg, J S Cameron.   

Abstract

Chemiluminescence and flow cytometry, employing a number of monoclonal antibodies, was used to investigate activation of immunocompetent cells in the blood and peritoneum of patients treated with CAPD. Increased expression of HLA-DR and RFD7, both markers of macrophage maturation, was observed on peritoneal macrophages, 78% and 33.5% cells positive, when compared to blood monocytes, which were 46% and 5.3%, respectively (P less than 0.001). Macrophage chemiluminescent response to opsonized zymosan was greater than that of circulating blood monocytes in CAPD patients, whereas the inverse was true for normal controls. Enhanced expression of IL-2 receptor and surface IgG by peritoneal macrophages were 24.9% and 65.3% cells positive compared with monocytes, 5.7% and 12.3% (P less than 0.01), and also suggests their activation. There was a marked increase in the HLA-DR expression by peritoneal lymphocytes from CAPD patients (32% cells positive) compared with those from CAPD blood (13.8%), normal blood (11.3%) and normal peritoneal fluid (14.5%), P less than 0.001. This was partially accounted for by increased numbers of B cells (18%) and activated T cells bearing HLA-DR. TFR and IL-2 receptor expression by CAPD peritoneal lymphocytes was similar to that of blood lymphocytes, implying the lack of an organized immune response within the peritoneum. Taken together, these results suggest that peritoneal macrophages from CAPD treated patients have features of maturation and activation, while changes in the lymphocyte populations are compatable with the actions of IL-1, indicating activity of the cellular immune system within the peritoneum.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2811064     DOI: 10.1038/ki.1989.243

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

1.  Functional effector memory T cells enrich the peritoneal cavity of patients treated with peritoneal dialysis.

Authors:  Gareth W Roberts; Duncan Baird; Kathleen Gallagher; Rhiannon E Jones; Christopher J Pepper; John D Williams; Nicholas Topley
Journal:  J Am Soc Nephrol       Date:  2009-08-27       Impact factor: 10.121

2.  IL-4 suppresses IL-1 beta, TNF-alpha and PGE2 production by human peritoneal macrophages.

Authors:  P H Hart; R L Cooper; J J Finlay-Jones
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

3.  Intraperitoneal immunization of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA response.

Authors:  C Lue; A W van den Wall Bake; S J Prince; B A Julian; M L Tseng; J Radl; C O Elson; J Mestecky
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

4.  Interleukin-8 production by human mesothelial cells after direct stimulation with staphylococci.

Authors:  C E Visser; J J Steenbergen; M G Betjes; S Meijer; L Arisz; E C Hoefsmit; R T Krediet; R H Beelen
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

5.  Antigen-presenting capacity of macrophages and dendritic cells in the peritoneal cavity of patients treated with peritoneal dialysis.

Authors:  M G Betjes; C W Tuk; D G Struijk; R T Krediet; L Arisz; R H Beelen
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

Review 6.  Host defences in continuous ambulatory peritoneal dialysis and the genesis of peritonitis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

7.  Intraperitoneal production of erythropoietin with continuous ambulatory peritoneal dialysis.

Authors:  M Chandra; G Clemons; I Sahdev; M McVicar; P Bluestone
Journal:  Pediatr Nephrol       Date:  1993-06       Impact factor: 3.714

8.  Specific increase in interleukin-8 concentrations in dialysis fluid of patients with peritonitis receiving continuous ambulatory peritoneal dialysis.

Authors:  Y C Ko; N Mukaida; T Kasahara; S Muto; K Matsushima; E Kusano; Y Asano; Y Itoh; Y Yamagishi; T Kawai
Journal:  J Clin Pathol       Date:  1995-02       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.